# Pharmacokinetics and Safety of M107 Orally Disintegrating Tablet in Healthy Adults

> **NCT07056517** · PHASE1 · COMPLETED · sponsor: **Aclipse Two Inc.** · enrollment: 21 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** M107 and Duvie - Cohort 1
- **DRUG:** M107 - Cohort 2
- **DRUG:** M107 - Cohort 3

## Key facts

- **NCT ID:** NCT07056517
- **Lead sponsor:** Aclipse Two Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-07-11
- **Primary completion:** 2025-09-22
- **Final completion:** 2025-09-22
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07056517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07056517, "Pharmacokinetics and Safety of M107 Orally Disintegrating Tablet in Healthy Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07056517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*